
Insilico Secures $2.75B Lilly Deal
Insilico Medicine entered a $2.75 billion global licensing deal with Eli Lilly for an AI-discovered oral GLP-1 drug. The agreement includes a $115 million upfront payment. This partnership underscores AI's role in accelerating drug discovery.







